Nemolizumab (TBC) for the Treatment of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Aged 12 Years and Older
Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for nemolizumab (TBC) for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable, and/or who are refractory to or ineligible for systemic immunosuppressant therapies.